Highlights

  • The filing, announced to the ASX on Monday, starts the formal US review process for the product Optiscan sees as its main commercial opportunity.
  • InVue is built on Optiscan's confocal laser endomicroscopy technology and is designed to let surgeons look at tissue under microscopic magnification in real time while the patient is still on the table.
  • The clinical groundwork for the filings has been building through 2026.
  • Even so, the FDA can, and frequently does, come back with questions or requests for additional information, which can stretch the timeline.

Melbourne medical imaging company Optiscan Imaging (ASX:OIL) has lodged a 510(k) premarket notification with the US Food and Drug Administration for InVue, its device for viewing tissue at the cellular level during cancer surgery. The filing, announced to the ASX on Monday, starts the formal US review process for the product Optiscan sees as its main commercial opportunity.

It is the second FDA submission from the company in less than a week. On 1 October, Optiscan filed a separate 510(k) for InForm, a digital pathology platform designed to work alongside InVue. Together the two filings deliver on a target the company had set for the second half of calendar 2026.

InVue Enters the US Review Process

InVue is built on Optiscan's confocal laser endomicroscopy technology and is designed to let surgeons look at tissue under microscopic magnification in real time while the patient is still on the table. The core problem it targets is surgical margins. In operations such as breast-conserving surgery, surgeons aim to remove a tumour with a rim of healthy tissue, but confirmation that no cancer cells remain at the edges usually comes from a pathology lab days later. If margins turn out to be involved, patients can face a second operation.

Optiscan is pitching InVue across a range of solid tumours, including breast, head and neck, colorectal, genitourinary and skin cancers. The company cites around 1.27 million Americans undergoing cancer surgery each year, a surgical oncology market it values at about US$4.8 billion annually, and a broader intraoperative imaging market forecast to reach US$1.55 billion by 2030.

Real-Time Imaging Targets Surgical Margins

Managing director Dr Camile Farah described the lodgement as another key deliverable in the company's broader strategy, arguing the technology could change what surgeons are able to see during an operation.

The clinical groundwork for the filings has been building through 2026. In July, Optiscan signed a research agreement with the Mayo Clinic for a 35-patient study using both InVue and InForm in lumpectomy procedures, with recruitment open and the site already initiated. A head and neck cancer study is also running at St John of God Murdoch Hospital in Perth. Separately, the company launched its InSpecta device into the US veterinary market in July, after submitting a dossier to the FDA's Center for Veterinary Medicine in March.

Clinical Work Supports the Filing

The 510(k) pathway requires a company to show its device is substantially equivalent to a product already legally on the US market, and is generally faster and cheaper than full premarket approval. Even so, the FDA can, and frequently does, come back with questions or requests for additional information, which can stretch the timeline. Optiscan has not put a firm date on a decision and acknowledged the agency may seek clarification before ruling.

Rather than wait for clearance, the company says it will push ahead with clinical reference sites, surgeon partnerships, Manufacturing scale-up and talks with potential commercial partners, so it is ready to sell if and when the regulator signs off.

FDA Feedback Becomes the Next Marker

Funding that effort will be a focus. Optiscan held about A$15.1 million in cash at 31 March 2026 and is still generating only small revenues, having reported A$339,227 for the half to December 2025 alongside a net loss of A$3.4 million. Market data compiled by TipRanks put its Market Value at roughly A$172 million around the time of the filing. The share price reaction to the InVue lodgement could not be independently confirmed, although Grafa reported the stock held flat at 13.5 cents after the InForm filing earlier in the week.

Key items to watch now are any FDA correspondence on either submission, first data from the Mayo Clinic study, and whether Optiscan can land a commercial or distribution partner for the US market while the reviews run.

What Will the FDA Say Next?

Attention now turns to the next operational, clinical, exploration or regulatory milestones outlined by Optiscan Imaging, with upcoming results and execution set to determine how the current development pathway progresses.